Total Revenue

18.6% increase

Total revenue rose to $54.169 million in Q4 2024 from the previous period, driven primarily by the continued acquisition of new customer locations—a key growth lever previously noted in earlier quarters—and strong platform demand. " "

Subscription and Payment Processing Revenue

19% increase

The segment increased from $43.73 million to $52.12 million in Q4 2024, reflecting the same underlying trend seen in past periods where new customer additions boosted recurring revenue growth through subscriptions and payment processing services. " " "

Gross Profit

Margin improved to 72%

Gross profit reached $39.044 million with an implied margin of about 72%, benefiting from the higher revenue base and improved operational efficiency that built on previous quarter trends of margin expansion, cost management, and the leverage of high-margin recurring revenue streams. "

Sales & Marketing Expenses

20% increase (from $18.291M to $21.934M)

The significant rise in sales and marketing expenses reflects increased investment in personnel—driving higher stock‐based compensation, commissions, and bonuses—and greater spending on demand generation initiatives (similar to earlier quarters’ trends), underlining continued strategic focus on expanding market penetration. " "

R&D Expenses

18% increase (from $9.133M to $10.76M)

The rise in R&D spending is largely due to enhanced investment in platform development, marked by higher headcount, salary adjustments, and stock‐based compensation, echoing similar cost drivers observed in previous periods aimed at supporting product innovation and infrastructure improvements. " "

Net Loss

Improved by approximately 4.7% (from $(7.039)M to $(6.711)M)

Although expenses increased across several categories, the net loss improvement reflects the offsetting impact of robust revenue growth and enhanced gross margins, following a pattern seen in previous quarters where operational efficiency and higher recurring revenue helped narrow the net loss gap. " "

Total Revenue

Q4 2024

$52.6 million to $53.6 million "

no current guidance

no current guidance

Non-GAAP Operating Income

Q4 2024

$0.9 million to $1.9 million "

no current guidance

no current guidance

Total Revenue

FY 2024

$202.7 million to $203.7 million "

no current guidance

no current guidance

Non-GAAP Operating Income

FY 2024

positive "

no current guidance

no current guidance

Weighted Average Share Count

FY 2024

Approximately 71.6 million shares "

no current guidance

no current guidance

Total Revenue

Q1 2025

no prior guidance

$54 million to $55 million "

no prior guidance

Non-GAAP Operating Income

Q1 2025

no prior guidance

negative $0.7 million to positive $0.3 million "

no prior guidance

Total Revenue

FY 2025

no prior guidance

$232 million to $237 million "

no prior guidance

Non-GAAP Operating Income

FY 2025

no prior guidance

$2 million to $6 million "

no prior guidance

Weighted Average Share Count

FY 2025

no prior guidance

Approximately 75.9 million shares "

no prior guidance

Specialty Medical Expansion

Q1 discussions highlighted expansion into specialty medical subverticals such as physical therapy, medical aesthetics, plastic surgery, and primary care with clear product‐market fit. " " Q2 emphasized rapid revenue reacceleration, with revenue growing at double the overall rate and very low market penetration (<0.5%). " " " " Q3 continued this focus by noting plans to expand from 4 to 8 subverticals and strong growth in MedSpas and general practitioners. " " "

Q4 placed strong emphasis on specialty medical expansion with detailed integration updates (eClinicalWorks, athenahealth, dr chrono, NextGen) supporting a subvertical that grew at twice the overall rate, and mentioned market penetration is still under 1%. "

Consistent emphasis across quarters with increasing optimism and broader integrations in Q4 that reinforce its growth potential.

Payments Strategy

Q1 discussions flagged underperformance with attach rates “way below where they need to be” and noted challenges with integration and leadership focus. " " Q2 mentioned enhancements in digital collections and the appointment of a new General Manager to drive adoption. " " Q3 focused on robust growth, emphasizing that payments were growing faster than overall revenue and were a key growth driver. " "

Q4 highlighted substantial team expansion, new integrations with major practice management systems, and product enhancements (payment plans and reminders); no mention of underperformance, instead emphasizing payments as an accretive growth area. " "

Sentiment improved significantly from early underperformance concerns to a robust strategic focus and positive growth trajectory.

NRR Dynamics

Q1 reported an increase from 95% to 96% driven by payments adoption and software upsells. " " Q2 showed further improvement to 97%, attributing gains to upsell motions and favorable pricing adjustments. " " Q3 saw NRR rise to 98% by integrating payments growth and additional upsell products. " "

Q4 maintained NRR at 98%, bolstered by targeted price adjustments for additional functionality and the continued influence of improved customer contributions. " "

Steady, incremental improvement with a consistently positive trend across periods.

Practice Management System Integrations & New Platform Adoption

Q1 focused on deepening integrations with PMS partners—emphasizing a win‐win partnership approach and advancing integration levels from basic to advanced. " " Q2 detailed the rollout of 20 new integrations along with the launch of a new product platform (new SMB app and Weave Enterprise) that boosted usability. " " Q3 discussed increased inbound interest from PMS vendors and early successes in new platform adoption through enhanced functionalities. " "

Q4 reported further expansion by integrating with additional systems (eClinicalWorks, athenahealth, dr chrono, NextGen, Opendental, Patterson’s Eaglesoft/Fuse, Prompt, Practice Fusion) and underscored improved customer adoption of the new platform enriched with AI-powered features like Call Intelligence. " " "

Steady growth with increasing integration depth and new platform adoption, reflecting a maturing strategy.

Strategic Partnerships

Q1 mentioned early strategic partnerships with players such as Patterson Veterinary, IDEXX, Athenahealth, and Prompt EMR to expand market reach. " " Q2 celebrated a major commercial partnership with Patterson Dental, unlocking access to 100,000 locations. " " Q3 detailed training initiatives with Patterson Dental (e.g., training 700 sales reps) and highlighted strong co-marketing benefits. " " "

Q4 reinforced the value of strategic partnerships, highlighting the enhanced co-marketing and co-selling efforts with Patterson Dental that have driven increased bookings and payments revenue, and signaling plans for further expansion in 2025. "

Consistent emphasis on strategic partnerships with a deepening of collaboration over time and positive impact on sales metrics.

Revenue Growth & Pricing Adjustments

Q1 reported steady revenue growth (e.g., $47.2 million) driven by upsells and modest price adjustments that improved ARR. " " " Q2 underscored strong revenue acceleration (e.g., $50.6 million with 21.4% YoY growth) and effective quarterly pricing updates. " " " Q3 disclosed over 20% YoY growth with continued experimentation in pricing adjustments, demonstrating customer tolerance for value‐driven increases. " " "

Q4 delivered 19% YoY revenue growth ($54.2 million) and noted that the most significant pricing adjustments had occurred in Q2 2024, with stabilization occurring thereafter. " "

Consistent high growth supported by a mature and effective pricing strategy that has been refined over successive quarters.

Gross Margin Improvement

Q1 showed a milestone improvement to 70.4% (a 280 bps jump), marking the beginning of a steady enhancement cycle. " " Q2 improved further to 71.9% on the back of cost efficiencies and economies of scale. " " Q3 saw margins reach 72.5%, aided by payments product expansion and operational enhancements. " "

Q4 continued this positive trend with gross margins at 72.6%—a 290 basis point improvement YoY and the 12th consecutive quarter of sequential improvement, reflecting sustained operational discipline. "

Steady, sequential improvement confirming ongoing operational efficiencies and cost management.

AI Product Implementation

Q1 did not discuss AI-related offerings. Q2 began mentioning the development and potential of AI-driven solutions leveraging the company’s data. " " " Q3 emphasized successful integration of AI-powered features such as Weave Assistant and Call Intelligence that provided immediate customer value. "

Q4 provided a detailed monetization strategy for AI products, outlining bundling approaches (good, better, best) and upsell opportunities with products like Call Intelligence and Assistant; the implementation is now tied directly to enhanced ASPs while managing pricing carefully. " "

Emerging topic that gained clarity over time and now has an explicit monetization strategy, reflecting increasing focus and value realization.

Increased Compliance Costs

Not mentioned in Q1, Q2, or Q3 discussions.

Introduced in Q4 as a new regulatory topic with the announcement that 2025 will be the first year subject to Section 404(b) of Sarbanes-Oxley, leading to increased compliance and audit fees, partly driven by seasonal factors in Q1 2025. "

New topic emerging in Q4 that signals upcoming increased expenses due to compliance requirements.

Growth Initiatives Investment

Q1 provided indirect signals of growth focus via investments in expanding into various markets and integrations. " " " Q2 detailed explicit investments in specialty medical, strategic partnerships, and new product development while managing some margin pressure (e.g., higher sales/marketing spend). " Q3 did not explicitly focus on this topic.

Q4 underlined continued targeted investments in growth initiatives—particularly in AI, specialty medical markets, and expanded partnerships—while also highlighting improved margin performance and disciplined cost management (e.g., achieving a 3.3% operating income margin). " "

Consistent focus on growth with ongoing investments that are now delivering improved margin outcomes, even as explicit mentions varied.

Future Growth Guidance

Q1 guidance was positive with revenue forecasts and emphasis on accelerating growth in key markets (dental, optometry, veterinary, specialty medical). " " Q2 maintained an optimistic outlook with raised full‑year guidance and confidence in core performance along with resilience from customers. " " Q3 forecasted steady growth and a stable revenue run rate with emphasis on specialty medical’s high growth rate. "

Q4 guidance pointed to an acceleration in the second half of 2025 with strategic investments set to boost growth beyond current levels; the outlook remains positive even after challenging prior comparison cohorts, with 2025 revenue projected in the range of $232–$237 million. " "

Consistently positive outlook that has evolved toward expecting accelerated growth in the near future, particularly in H2 2025.

Integration Challenges & Migration Resistance

Q1 acknowledged challenges in migrating customers to new platforms and the effort needed to build deeper PMS integrations to “stickify” the product. " " " Q3 addressed these issues by noting that while customers can be resistant to change, proactive PMS vendor interest and strategic integrations helped reduce friction. "

Q4 did not mention integration challenges or customer migration resistance, indicating that these issues have become less prominent in discussions [–].

Reduced emphasis relative to earlier quarters, suggesting smoother integrations and less customer resistance to migration as the strategy matures.